

PATIENT PATHWAY GUIDE

THE remede $\bar{\rm e}^{\rm @}$ SYSTEM PATIENT PATHWAY GUIDE

Overview and Justification	3
The remedē Patient Pathway	4
Phase 1 – Screening for Sleep Disordered Breathing (SDB)	4
Background and Prevalence of SDB	
Pre-Screening Questionnaires	
Sleep Apnea Testing	
Screening Resources	
Phase 2 – Patient Selection – Treatment Decisions in Central Sleep Apnea	8
Alternative Therapies	
Identifying Existing CSA Patients	
Patient Education for the remedē System	
Patient Selection Resources	
Phase 3 – rem edē System Implant	15
Implant Procedure Overview	
Postoperative Considerations	
Implant Resources	
Phase 4 – Optimization and Follow Up	. 18

Overview and Justification

The **rem**edē[®] System was approved by the FDA in 2017 for the treatment of moderate to severe central sleep apnea (CSA) in adult patients. The device delivers phrenic nerve stimulation therapy to restore normal nighttime breathing. 151 patients with CSA, who had an Apnea Hypopnea Index (AHI) \ge 20 events/hour and a Central Apnea Index (CAI) of at least 50% of all apneas, were enrolled in the **rem**edē Pivotal Trial. 91% of patients in the trial experienced an improvement in AHI at 12 months, while 79% had improvement in quality of life. Moreover, improvements in central apnea events, arousals, sleep quality and daytime sleepiness were maintained through 36 months in both the treatment and former control groups. The pivotal trial demonstrated a strong safety profile as well with 91% freedom from serious adverse events (SAE).^{1,2}

Patient Pathway Description

In working with many different institutions with **rem**edē programs, we have established that the **rem**edē patient pathway can be divided into four distinct phases: Screening for sleep disordered breathing, patient selection, device implant, and therapy optimization and follow up. Each of these phases will be outlined in this document. The protocol examples herein are based on experience with programs of varying size and structure and are provided to guide successful development of a clinical pathway for patients who may benefit from treatment with the **rem**edē System.

The remedē Patient Pathway

PHASE 1 — SCREENING FOR SLEEP DISORDERED BREATHING

Background and Prevalence of SDB

Sleep disordered breathing (SDB) is estimated to affect up to 2 million Americans, with 80% of those patients having predominantly Obstructive Sleep Apnea (OSA), and about 20% having predominantly Central Sleep Apnea (CSA).³ However, CSA is much more prevalent in cardiovascular patient populations.⁴

SDB is the most common comorbid condition in patients with heart failure (HF), as nearly three-quarters of all heart failure patients have some form of SDB. It is estimated that half of those suffer from predominantly Central Sleep Apnea.⁴ Additionally, approximately 40% of patients with heart failure with reduced ejection fraction (HFrEF) have CSA.⁵ CSA is associated with a two-fold increase of both HF hospitalizations and mortality among HF patients and can cause symptoms that resemble those commonly associated with HF.⁶⁻⁸ Additionally, CSA has predicted new-onset HF in long-term prevalence studies.⁹

SDB is also prevalent in patients with Atrial Fibrillation (AF), with an estimated 74% of patients with AF having some form of SDB.¹⁰ CSA is associated with a 2- or 3-fold increase in risk of developing AF.¹¹

Pre-Screening Questionnaires


Patients with CSA often do not display common symptoms associated with SDB such as snoring and daytime sleepiness.¹² Common pre-screening questionnaires have not been validated in CSA and can fail to identify these patients, but can help identify risk factors for and symptoms of SDB.^{12,13} The Epworth Sleepiness Scale (ESS), STOP-BANG and the Berlin Questionnaire have all be shown to have limited reliability in patients with cardiovascular (CV) disease.¹³ Literature suggests that STOP-BANG scoring of \geq 3 may be more reliable for detecting SDB in CV.¹⁴ More general questions to assess HF patients for symptoms of excessive daytime fatigue, observed apneas, nocturnal dyspnea and impaired cognition may more accurately identify patients who need further screening for sleep apnea.¹⁵ Respicardia has an example of a generic, though unvalidated, questionnaire in the Unbranded Patient Educational Brochure, which is included in the resources for this section.


Opportunities for screening in cardiovascular settings include:

- Initial heart failure consultation visits
- Post discharge clinic visits following HF-related hospitalization
- Atrial Fibrillation patients prior to ablation procedures
- Cardiac device patients with documented Implantable Cardiac Defibrillator (ICD) shocks or arrythmias, particularly during nighttime hours

Sleep Apnea Testing

Sleep apnea testing can be performed with either home testing equipment (HSAT) or through in-lab polysomnography (PSG). Several available HSAT units can differentiate between obstructive and central apnea events, but home studies tend to underestimate the disease due to their inability to assess sleep time.¹⁶ Patients with complex sleep apnea or other sleep-related issues may require PSG to accurately diagnose the burden of SDB. However, many factors including patient preference, sleep lab availability and insurance payer criteria may contribute to testing decisions. Refer to **Figure 1** – Outpatient Sleep Testing Decision Tree Example for one pathway option. An order template for sleep testing is included in the resources for this section.





FEELING TIRED AND FATIGUED? POOR SLEEP MAY BE CONTRIBUTING TO YOUR HEART DISEASE.

Do you have trouble concentrating?

Have you ever been told that you stop breathing while you sleep?

Have you been told that you snore when you sleep?

Have you ever been told you have Atrial Fibrillation?

Have you ever been told you have Heart Failure?

Have you been told in the past that you had Sleep Apnea?



WHY IS IT IMPORTANT TO BE EVALUATED FOR SLEEP APNEA?

Sleep apnea is a common condition for heart failure and atrial fibrillation (AFib) patients.



Sleep apnea is a serious condition associated with hospitalizations, heart attacks, and even death^{1,2}



Sleep apnea symptoms – **fatigue**, **brain fog, and sleepiness** – are similar to those of heart failure and AFib or AFib have **sleep apnea**^{3,4}

Half of people with heart failure

Sleep testing can be done in a single night, and often **in your own home**



Many treatment options are available, including those that **don't require a mask**

Talk to your healthcare provider today

to see if you should be tested for sleep apnea.

Patient Name:	
nsurance Info:	
Ordering Provider:	NPI
I. STUDY REQUESTED	
Unattended Home Sleep Apnea Test (HSAT)	G0398 G0399 95800 95801 95806
Attended In-Lab Diagnostic PSG 95810	46556, 46555, 55666, 55661, 55666
	TION (CHECK ALL THAT APPLY IN A-D)
	ION (CHECK ALL THAT APPLT IN A-D)
A. What is the Suspected Diagnosis?	
Sleep Apnea, unspecified G47.30	persomnia, unspecified G47.10
B. Signs and Symptoms (check all the apply)	
Evidence of Excessive Daytime Sleepiness A	ND Evidence Suggestive of Sleep Disordered Breathing
Disturbed or restless sleep	Gasping or choking during sleep
non-restorative sleep/non-refreshing sleep	Witnessed apnea events
Frequent unexplained arousals from sleep	Cognitive deficits such as concentration/memory
Fragmented sleep	Morning headache
Fatigue	Experienced Apneas/Hypoxemia under anesthesia
Waking feeling tired	Snoring
Duration of signs and symptoms: Less than a	one month Greater than one month
C. Co-morbid Conditions (check all that apply)	
Pulmonary Hypertension	
Moderate to severe pulmonary disease	
	NYHA class III or IV) or LVEF lower or equal to 45%
Neuromuscular/neurodegenerative disorder	
Chronic opioid medication use (include curre	ent med list/fa/dose)
Refractory Atrial fibrillation or nocturnal dysrb	
No known comorbid conditions	
No known contorbid conditions	
D. Epworth Sleepiness Scale Score: OR	STOP-Bang Score:

PHASE 2 – PATIENT SELECTION: TREATMENT DECISIONS IN CENTRAL SLEEP APNEA

Alternative Therapies

Despite several therapeutic options for OSA, CSA treatment is less-well defined in clinical data. To date, mask-based pressure therapies, oxygen, and a small number of medications have been evaluated in the treatment of CSA.¹⁸ These treatment modalities for CSA have demonstrated limited effectiveness, poor adherence, and potential safety concerns in some populations.^{17,19} Specifically, Adaptive Servo-Ventilation (ASV) is contraindicated in patients known to have heart failure with left ventricular ejection fraction of <45%.¹⁸ CPAP and other therapies may be appropriate as first-line treatment in some patients with CSA.²⁰ Patients should be seen for follow up evaluation to assess effectiveness, compliance and tolerability based on individual clinical discretion. **Figure 2** illustrates one potential decision algorithm that may be used for determining candidacy for **rem**edē therapy.

Identifying Existing CSA Patients

Patients previously established in sleep medicine clinics with CSA-predominant SDB can be identified though searching existing databases, including electronic medical records (EMR), sleep software databases, and compliance software programs used to monitor PAP use for multiple durable medical equipment (DME) companies. Such database searches are easy to perform and typically do not require facility Information Technology (IT) personnel to conduct.

Patient Education for the remedē System

Once patients are identified as potential candidates for the **rem**edē System for treatment of CSA, discussion about the device often occurs in both Sleep Medicine and Electrophysiology clinic settings. Patients and caregivers most often have questions and concerns about the implant procedure and how the therapy feels when active, along with general questions about CSA. The implant procedure is reviewed in section 3 below. Patients are often reassured that electrophysiologists perform similar procedures, such as pacemaker implants daily. An outline for patient discussion, as well as some of the most frequently asked questions are provided in the following pages. Patient brochures describing the therapy and procedure, as well as, the **rem**edē Frequently Asked Questions booklet are available for these discussions from your **rem**edē representative.




Figure 2 – remedē[®] Patient Selection Pathway Example

Dear, _____

Our records indicate that your last visit for sleep apnea follow up was DATE. Dr XX (or provider) would like to schedule a follow up visit to talk about how you are sleeping and whether your [insert current therapy] is working for you. Since your last follow up, we have new treatment options available that could potentially help treat your sleep apnea without the use of a mask at night.

At your earliest convenience, please call the [Sleep Medicine department at PHONE], Monday through Friday, 8:00 am to 4:00 pm to schedule an appointment. If you have any questions before your visit, please feel free to call us.

Dear, _____

When reviewing you CPAP data, we noticed that you may be having issues wearing your mask, or that it is not working ideally. [insert Dr/provider name] would like to schedule a follow up visit to talk about how you are sleeping and whether your [insert current therapy]) is working for you. New treatment options are now available that could potentially help treat your sleep apnea without the use of a mask at night.

At your earliest convenience, please call the [Sleep Medicine department at PHONE], Monday through Friday, 8:00 am to 4:00 pm to schedule an appointment. If you have any questions before your visit, please feel free to call us.

Review Central Sleep Apnea

- Obstructive vs Central Sleep Apnea
- remedē website resource: remede.zoll.com/central-sleep-apnea
- Review any past treatment experiences the patient has tried

How remede works to treat CSA

- Overview video can be used here: remede.zoll.com/remede-system
- Show demo device

remedē Implant Procedure

- Implant typically outpatient procedure in cardiac cath lab
- Very similar to pacemaker implantation by cardiac electrophysiologists
- Video overview of implant and post-operative care available

Device Activation and Follow Up

- Therapy activated at a clinic visit 4-6 weeks following the implant procedure
- How the therapy activates (See FAQ)
- How the therapy feels (See FAQ)
- Hear from other remedē patients: remede.zoll.com/hear-from-others

Central Sleep Apnea

What is the difference between Central Sleep Apnea (CSA) and Obstructive Sleep Apnea (OSA)?

Obstructive sleep apnea (OSA) and central sleep apnea (CSA) are both types of sleep apnea. In OSA, the breathing muscles (e.g. diaphragm) are activated appropriately but a narrowing of the passages in the upper airway (the tongue or throat) cause a blockage that prevents air from flowing freely. The obstruction can be due to bodily features or a relaxation of the muscles in the chest and neck during sleep. In CSA, the brain fails to send regular signals to the diaphragm. The lack of consistent signals leads to irregular nighttime breathing. Some people have both OSA and CSA and this is sometimes called complex sleep apnea. Determining how to address complex sleep apnea will take consideration and consultation with your physician regarding managing the complete picture of your sleep apnea.

The remede® System

What is remedē?

remedē is a pacemaker-like device that stimulates your breathing muscles (via the phrenic nerve) to restore a normal breathing rate and rhythm during sleep. It is fully implantable and activates automatically each night.

How does remede work?

remedē activates automatically each night to send signals to your diaphragm from the phrenic nerve to restore a normal breathing pattern. The signals cause your diaphragm to contract, drawing air into your lungs, just as in normal breathing. **rem**edē also monitors breathing signals while you sleep. Because the device is implanted and activates automatically, it does not require wearing a mask or other equipment at home.

What does remedē feel like?

In our experience, most people describe their first breaths with **rem**edē as taking a breath that you didn't plan on. Once activated, **rem**edē is designed to turn on once you are already asleep and operate without waking you up.

When will remedē activate at night?

The **rem**edē System is programmed to automatically begin therapy each night when **all three** of the following programmable conditions are met:

- 1) Sleeping hours: It is within your normal sleeping times; (for example, 11:00 PM to 6:00 AM)
- 2) Sleeping posture: You are in a sleeping posture (for example, a horizontal position)
- 3) Activity: Your activity level is representative of a sleeping or resting condition

Can I pause or turn remedē off?

If you roll over, sit up, or get out of bed, the therapy will pause and resume once the above three conditions are once again met.

The Implant Procedure

What are the risks associated with the remede procedure or therapy?

As with any surgically implanted device, there are risks related to the implant procedure which may include, but are not limited to, pain, swelling and infection. Once the **rem**edē System is implanted and the therapy is activated, some people may experience discomfort from the therapy and/or from the presence of the device. The majority of these events are resolved on their own or by adjusting the therapy settings. The **rem**edē System may not work for everyone. There are additional risks associated with removing your system. If you and your doctor decide to remove the system, another surgery will be required.

What happens during the procedure?

The **rem**edē System is placed during a minimally invasive procedure by a cardiologist. The system is a battery powered device placed under the skin in the upper chest area with two small thin wires (leads), one to deliver the therapy (stimulation lead) and one to sense breathing (sensing lead).

How long does the battery last?

The latest models of the **rem**edē System have batteries that typically last between 4-6 years. Some people may not need replacement for over 6 years. However, if higher levels of therapy are needed to normalize breathing, the battery may need to be replaced in 2 years or less.²¹

Will I have any limitations following the procedure?

Follow all advice from your doctor after the procedure. Most people can resume normal activity 7-10 days after he procedure. In most cases, your doctor will advise you to not raise your arm above the shoulder on the side the device is placed for 1-3 months.

What follow up visits are required?

You typically return about one month after implant to activate therapy. During this time, you recover and the device collects data on your sleeping and breathing patterns. At the visit, the clinician will activate and program **rem**edē to meet your needs. People typically return for additional clinic appointments to adjust programming and titrate the therapy. Once optimized, most clinicians will follow up 1-2 times per year.

Coverage and Cost

How much will I have to pay for remede?

The hospital will work with your insurance plan to determine what, if any, of the cost is billed to you. Talk to your physician about insurance coverage, as many insurance companies work with clinicians to evaluate coverage for **rem**edē based on your individual case.

Is this therapy covered by insurance?

remedē is generally being reviewed for approval by insurance providers on a case-by-case basis. After determining that you are a candidate for **rem**edē, your doctor and their office staff will work with your insurance provider on securing coverage for the procedure.

What happens if the procedure is denied by my insurance company?

In most cases, you are able to appeal a denial by your insurance company and request further review of your case. Ask your physician about the **rem**edē Patient Access Program, which provides resources for supporting insurance prior authorization appeals.

[DATE]		[PHYSICIAN'S LETTERHEAD]	rem edē® System
[DR. NA	MEI		
[CENTE			
ADDRE	-		
CITY, ST			
Dear Dr.	[NAME]:		
(CSA). C some pa	CSA is a serious breathing disor atients with CSA can be treate	THER PHYSICIAN SPECIALTY], you likely encounter p rder leading to poor cardiovascular outcomes and ne d adequately, others may fail to respond to availab ity to effectively titrate, poor long-term compliance,	gatively affecting quality of life. While le treatment options and remain
challeng	es you have encountered wit	h central sleep apnea patients.	
that activ maintain	vates automatically each night	or adult patients with moderate to severe central slee t. It uses electrical signals to stimulate the phrenic r n and rate while the patient is sleeping. It is approv	nerve and activate the diaphragm,
		rough clinical trials to substantially improve sleep a a Index (CAI) and 67% reduction in Apnea-Hypopne	
		ygenation, and % REM sleep ²	
	82% of patients reported an ir		
		would "elect to have the medical procedure again"	13
•	5-year data published in Natur	e and Science of Sleep ⁴ demonstrates sustained eff	icacy and safety of the therapy
pacema	ker implant. Therapy is activa	ophysiologist, in an outpatient procedure using simil ted approximately one month following implant. F programmable therapy settings.	
l would a therapy		ts in your daily practice, you consider referring pati	ents who may be candidates for this
		e therapy or would like to discuss a specific case, ple o working with you to offer an option for your patier	• •
Sincerel	ly,		
[DOCTO	R NAME]		
[TITLE]	UTION]		
		anual, submitted as part of FDA PMA P160039C; 2 Fox, H., Oldenb MR, et al. Am J Cardiol 2018; 121:1400-1408. 4 Costanzo MR, e	
mportant S The remedãe he remedãe herapies). T with another mplanted de some patient adjusting the system, anot lease visit r nfection. Se events. Rx Only. The	afety Information © System is indicated for moderate to System is appropriate. The remede® S he device is MR Conditional. The con- stimulation device such as a heart pace evice, there are risks related to the surg ts may experience discomfort from stim t therapy settings. The remedê System ther surgery will be required. Be sure to remede.zoil.com, call 952-540-4470 or e the Instructions for Use for complete aremede® System, remedê® EL System	severe Central Sleep Apnea (CSA) in adult patients. A doctor will system should not be implanted during an active infection and pati litions and precautions can be found in the remede System MRI g semaker or defibrillator; special testing will be needed to ensure the jical procedure itself which may include, but are not limited to, patilation and/or from the presence of the device. The majority of th may not work for everyone. There are additional risks associated ou understand all the risks and benefits associated with the implan email info@remede.zoli.com. Contraindications: The remede Sys information regarding the procedure, indications for use, contrain eam, and remede® EL-X System have received FDA approval.	need to evaluate the patient's condition to determine if ents will not be able to have diathermy (special heat juidelines manual. The remedé System may be used te devices are not interacting. As with any surgically n, swelling, and infection. Once the therapy is turned o lese events are resolved either on their own or by I with removing the system. If it is decided to remove th tation of the remedé System. For further information tem is contraindicated for use in patients with an active
CAUTION:	on Indications, Contraindications, Wa	E Mark approval. to sale by or on the order of a physician. Rx only. Prior to use, r rnings, Precautions, Adverse Events, and Operator's Instructions	

Procedure Overview

The **rem**edē System implant procedure is typically performed by electrophysiologists (cardiologists specializing in cardiac device placement). The procedure is similar to contemporary techniques used to implant cardiac implantable electronic devices (CIEDs).^{1,19} The implant procedure is performed in the cardiac electrophysiology laboratory under conscious sedation as the patient and physician must communicate during stimulation lead testing. Patient preparation and antibiotics are comparable to those used for (CIED) implants.¹⁹ The **rem**edē System is placed in the pectoral region, typically on the right side. A single stimulation lead is placed in either the left pericardiophrenic vein or the right brachiocephalic vein. A sensing lead may be placed into the azygous vein to detect respiration. The **rem**edē Pivotal Trial demonstrated a 97% implant success rate, including those patients with concomitant cardiac devices.¹ Potential adverse events associated with the implant procedure are similar to those of cardiac device procedures and are detailed in the **rem**edē System Implant and Clinician Use Manual.²²

Postoperative Considerations

Patient follow up after the implant is comparable to that of postoperative care for CIED procedures. A 7- to 14-day check of the surgical incision is recommended. To allow for lead stabilization and healing after the implant procedure, the **rem**edē System therapy should not be enabled for approximately 1 month following implant (<u>remedē® System Implant and Clinician</u> <u>Use Manual</u>).²² The **rem**edē device will be in monitoring mode during the period from implant to therapy initiation. This allows the device to collect information on the patient's sleeping patterns to include time, position, and hours of sleep.

Upon discharge, patients should be instructed as follows:

- It is normal to feel some discomfort from the surgical incision and to have some pain at the implant site for 2-6 weeks.
- It is best to limit the mobility of the right arm (or left arm if left-sided device placement) and avoid lifting the arm above shoulder level for several weeks after the implant procedure. This time period allows the leads and IPG to affix more securely in place and such movements could impair the healing process.
- Repetitive upper extremity activities and exercise can cause damaging stress and possible failure to permanent implanted leads. Active patients should be cautioned to avoid physical activities that could damage the implant site or the implanted system.
- Inform general practitioners and consulting physicians that the patient has an implanted stimulation system.
- Patients should carry the Device/Subject Identification Card at all times.

Resources

The following pages provide a procedure product reference guide and dictation template for the **rem**edē implant procedure.

Inventory Reference Guide

			PART/ORDER		MINIMUM INVENTORY QUANTITIES			
	ITEM	MANUFACTURER	NUMBER	DESCRIPTION	1 CASE	2 CASE	3 CASE	
	PG	ZOLL Respicardia	1001, 1100, 1600	rem edē PG	2	3	4	
	Lead	ZOLL Respicardia	4065, 4165, 4665	respi stim LQS, 65cm	2	3	4	
Manufacturer Specific	Lead	ZOLL Respicardia	3102, 3652	respi stim R Lead – 24mm dia., normal length	2	3	4	
	Lead	ZOLL Respicardia 3103, 3653 respi stim R Lead – 20mm dia., ext		respi stim R Lead – 20mm dia., extended length	1	1	1	
	Catheter	ZOLL Respicardia	7120-S	respi guide 120°	2	3	4	
	Catheter	Merit Medical	57538CS-WOR	2	3	4		
nufe	Catheter	Merit Medical	57538CSV-WOR	Impress 5F CS VERT Catheter, 75cm	2	3	4	
Ma	Accessory	Pressure Products	SS-SA-09	9F Sealing Adapter	2	3	4	
	Accessory	ZOLL Respicardia	1007	Test Adapter (Reps Carry)	2	3	4	
	Accessory	Medtronic	6232ADJ	Adjustable Slitter	2	3	4	
	Guidewire	Physician preference		0.014" Floppy	3	6	9	
	Guidewire	Physician	preference	0.014" Stiff	2	3	4	
Physician Preference	Guidewire	Physician	preference	0.018″	2	3	4	
	Guidewire	Physician preference		0.035" angled floppy	2	3	4	
	Guidewire	Physician preference		0.035" access J-wire	2	3	4	
	Accessory	Physician preference		Y-connector and hemostasis valve	2	3	4	
	Accessory	Physician preference		IS-1 standard Port plug (For models 1001, 1100)	3	5	7	
	Accessory	Physician preference		8Fr x 13cm hemostatic introducer sheath, splitable	2	3	4	
	Accessory	Physician preference		Disposable pacing cables	2	3	4	
	Accessory	Physician preference		Programming Wand Sterile Sleeve	2	3	4	
	Accessory	Physician	preference	Guidewire Torque Device	2	3	4	

Important Safety Information
The remedia® System is indicated for moderate to severe Central Sleep Apnea (CSA) in adult patients. A doctor will need to evaluate the patient's condition to determine if the remedia® System is appropriate. The remedia®
System Should not be implanted during an active infection and patients will not be able to have diathermy (special heat therapies). The device is MR Conditional. The conditions and percautions can be found in the remedia
System MR guidelines manual. The remedia® System may be used with another stimulation device such as a heart pacemaker or defibrillator; special testing will be needed to ensure the devices are not interacting. As with any
surgically implanted device, there are risks related to the surgical procedure itself which may include, but are not limited to, pain, swelling, and infection. Once the therape is turned on, some patients may experience disconflor
from simulation and/or from the presence of the device. The majority of these events are resolved either on their own or by adjusting the herapy settings. The remedia® System my on work for everyone. There are additional
risks associated with removing the system. If it decided to remove the system, another surgery will be required. Be sure to understand all the risks and benefits associated with the implantation of the remedia System sort on System Statemarks and the interaction. See the Instructions for Use
for sure to additional devices with remedia System or all 952-540-4470 or email info@memede.zoll.com. contraindications the remedia devices event. Incommon please via neuroeccus.com, cun 322346-4470 to enan monetaneladoccus, commentationes in territodo system a con for complete information regarding the procedure, indications for use, contraindications, warnings, precoutions, and potential adverse events. RX Ohy, The remede[®] System rode1000 has received CE Mark approval. The remede[®] System rode1000 has received CE Mark approval.

ZOLL MEDICAL CORPORATION

12400 Whitewater Dr., Suite 150 | Minnetonka, MN 55343 | 952-540-4470 | info@remede.zoll.com | remede.zoll.com

Copyright © 2023 ZOLL Medical Corporation. All rights reserved. Respicardia and **rem**edē are registered trademarks of ZOLL Respicardia, Inc. in the United States and/or other countries. ZOLL is a registered trademark of ZOLL Medical Corporation in the United States and/or other countries

Printed in the U.S.A. MKT0021, Rev H

For subsidiary addresses and fax numbers, as well as other global locations, please go to www.zoll.com/contacts.



DICTATION FORM

remedē[®] System

					F		PO	itient S	incident:	
e m edē Representative	:									
NI		Implanting Phy	sician							
Name:										
Phone:										
Hospital:				E a II an star	Dha shatara					
Name:				rollowing	Physician Phone:					
Hospital:					Phone:					
riospilai.				remedē li	nformation					
Model #:			Serial #				Implant Dat	æ.		
			ocnur in		ormation		inipidii bai	<u>.</u>		
		Company		Implant Da			odel #			Serial #
Left Stim	-	Respicardia (ZOLL)				141				
Right Stim		Respicardia (ZOLL)								
Sensing Lead										
Sensing Ledu	<u> </u>			Measu	red Data					
Cath(-)/Anode(+)	PW/Frequer			Impedance: Ohms			ERS (Y/N)		
	1	11171104001								
			B	est Pair/Con	comitant Test	ing				
		Best Pair					ncomitant D	evice 1	esting	
Cath(-) Anode(+)	Out	put: mA/PW/Freq	Imped	ance (ohms)	Company		/ICD/CRT		utput	Result
									•	
		Ex	cplanted	d/Capped/A	ttempted Not	t Implant	ed			
Company		Model #			rial #		Explant Date		Status	
				Device and L	ead/s Sticker	rs				
re	m edē			Sensin	ıg Lead			Stim	ulation Le	ad

Therapy Initiation Visit

• Four to six weeks following the implant procedure, the patient will be seen in clinic for therapy initiation. During this 1-hour visit, the **rem**edē device information will be analyzed and parameters customized to fit the patient's tolerability and sleeping patterns. The **rem**edē device will begin working that evening at the programmed sleeping start time, once it detects that the patient is in the sleeping posture and not moving. See the Patient Follow Up and Therapy Optimization Guide for detailed visit instructions.

Therapy Optimization Visits

• Therapy optimization visits of approximately 30-45 minutes will be scheduled every 6 to 12 weeks to allow for device assessment and programming changes to obtain optimal therapy for each individual patient. Patients typically require 2-to-3 follow up visits to achieve optimal therapy settings. See the Patient Follow Up and Therapy Optimization Guide for detailed visit instructions.

Long Term Follow Up

• Once therapy is optimized, clinic visits of 15-20 minutes should occur every 3 to 6 months to review the patient's subjective information, device data, and battery status.




Figure 3 – remedē[®] Device Optimization and Follow Up Pathway

Goal of Therapy

The goal for treatment with the **rem**edē[®] System is to normalize breathing. This may, however, be limited by patient tolerance or airway obstruction.

Target AHI

The target AHI should be determined by the physician based on patient tolerance and therapy efficacy at the second visit.

Optimization

Optimization is defined as attaining the AHI goal or reaching the maximum tolerated stimulation.

References

- ¹ Costanzo, MR, et. al. Transvenous Neurostimulation for Central Sleep Apnoea: A Randomised Controlled Trial. Lancet 2016; 388: 974–82.
- ² Fox, H, et. al. Long-Term Efficacy and Safety of Phrenic Nerve Stimulation for The Treatment of Central Sleep Apnea. Sleep J, 2019; 42(11): 1-9.
- ³ https://www.sleepapnea.org/learn/sleep-apnea-information-clinicians/.
- ⁴ Oldenburg, O, Lamp, B, Faber, L, Teschler, H, Horstkotte, D, Töpfer, V. Sleep-Disordered Breathing in Patients with Symptomatic Heart Failure. A Contemporary Study of Prevalence in and Characteristics Of 700 Patients. Eur J Heart Fail, 2007; 9(3):251-7.
- ⁵ Khayat, RN, Abraham, WT. Current Treatment Approaches and Trials in Central Sleep Apnea. International Journal Cardiology. 2016; 206: S22–S27.
- ⁶ Khayat, RN, Abraham, WT, Patt, B, Brinkman, V, Wannemacher, J, Porter, K, Jarjoura, D. Central Sleep Apnea is a Predictor of Cardiac Readmission in Hospitalized Patients with Systolic Heart Failure J Card Fail. 2012; 18(7): 534-540.
- ⁷ Khayat, RN, Jarjoura, D, Porter, K, Sow, A, Wannemacher, J, Dohar, R, Pleister, A, Abraham, WT. Sleep Disordered Breathing and Post-Discharge Mortality in Patients with Acute Heart Failure. European Heart Journal. 2015; 36, 1463–1469.
- ⁸ Artz, M, Woehrle, H, Oldenburg, O, Graml, A, Suling, A, Erdmann, E, Teschler, H, Wegscheider, K. Prevalence and Predictors of Sleep-Disordered Breathing in Patients with Stable Chronic Heart Failure. The SchlaHF Registry. JACC: Heart Failure. 2016; 4(2): 1 1 6–2 5.
- ⁹ Javaheri, S, Blackwell, T, Ancoli-Israel, S, Ensrud, KE, Stone, KL, Redline, S. Sleep-disordered Breathing and Incident Heart Failure in Older Men. Am J Respir Crit Care Med. 2016; 193{5}: 561-568.
 ¹⁰ Kadhim, K, Middeldorp, ME, Elliott, AD, Jones, D, Hendriks, JML, Gallagher, C, Artz, M, McEvoy, RD, Antic, NA, Mahajan, R, Lau, DH, Nalliah, C, Kalman, JM, Sanders, P, Linz, D.
- Self-Reported Daytime Sleepiness and Sleep-Disordered Breathing in Patients with Atrial Fibrillation: SNOozE-AF. Can J Cardiol. 2019; 35: 1457-1464.
- ¹¹ Tung, P, Levitzky, YS, Wang, J, Quan, SF, Gottleb, DJ, Rueschman, M, Punjabi, NM, Mehra, R, Bertisch, S, Benjamin, EJ. Obstructive and Central Sleep Apnea and the Risk of Incident Atrial Fibrillation in a Community Cohort of Men and Women. J Am Heart Assoc. 2017; 6(7). pii: e004500. doi: 10.1161/JAHA.116.004500.
- 12 Gupta, A, Quan SF, Oldenburg, O, Malhotra, A, Sharma, S. Sleep-Disordered Breathing in Hospitalized Patients with Congestive Heart Failure: A Concise Review and Proposed Algorithm. Heart Fail Rev. 2018; 23(5): 701–709.
- ¹³ Reuter, H, Herkenrath, S, Trem, M, Halbach, M, Steven, D, Frank, K, Castrogiovanni, A, Kietzmann, I, Baldus, S, Randerath, WJ. Sleep-Disordered Breathing in Patients with Cardiovascular Diseases Cannot Be Detected By ESS, STOP-BANG, and Berlin Questionnaires. Clinical Research in Cardiology. 2018; 107:1071–1078.
- 14 Labarca, G, Valdivia, G, Oñate, A, Navarrente, C, Araya, J, Fernandez-Bussy, I, Dreyse, J, Jorquera, J. Prevalence Of STOP BANG Questionnaire and Association with Major Cardiovascular Events In Hospitalized Population: Is It Enough With Currently Used Cardiovascular Risk Measurements? Sleep Medicine. 2019; 61: 82-7.
- 15 Kahwash, R, Khayat, RN. A Practical Approach to the Identification and Management of Sleep-Disordered Breathing in Heart Failure Patients. Sleep Med Clin. 2017; 12: 205–219.
- ¹⁶ Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479–504.
- ¹⁷ Bradley TD, Logan AG, Kimoff RJ, et al. Continuous Positive Airway Pressure for Central Sleep Apnea and Heart Failure. N Engl J Med 2005; 353: 2025–33.
- ¹⁸ Aurora RN, Bista SR, Casey KR, Chowdhuri S, Kristo DA, Mallea JM, Ramar K, Rowley JA, Zak RS, Heald JL. Updated Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline: "The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review And Meta-Analyses". J Clin Sleep Med 2016;12(5):757-761.
- 1º Cowie MR, Wegscheider K, Teschler H. Adaptive Servo-Ventilation for Central Sleep Apnea In Heart Failure. N Engl J Med 2016; 374: 690-91.
- 20 Augostini RS, Afzal MR, Costanzo MR, et al. How to Implant a Phrenic Nerve Stimulator for Treatment of Central Sleep Apnea? J Cardiovasc Electrophysiol. 2019; 1-8. https://doi.org/10.1111/jce.13898
- ²¹ FDA PMA P160039, Supplement 006, Physician Manual.
- ²² remedē[®] System Implant and Clinician Use Manual.

Important Safety Information

The remedē[®] System is indicated for moderate to severe Central Sleep Apnea (CSA) in adult patients. A doctor will need to evaluate the patient's condition to determine if the **rem**edē System is appropriate. The **reme**dē[®] System should not be implanted during an active infection and patients will not be able to have diathermy (special heat therapies). The device is MR Conditional. The conditions can be found in the **reme**dē System MRI guidelines manual. The **reme**dē System should not be implanted during an active infection and patients will not be able to have diathermy (special heat therapies). The device is MR Conditional. The conditions can be found in the **reme**dē System MRI guidelines manual. The **reme**dē System way be used with another stimulation device such as a heart pacemaker or defibrillator; special testing will be needed to ensure the devices are not interacting. As with any surgically implanted device, there are risks related to the surgical procedure itself which may include, but are not limited to, pain, swelling, and infection. Once the therapy is turned on, some patients may experience discomfort from stimulation and/or from the presence of the device. The majority of these events are resolved either on their own or by adjusting the therapy settings. The **reme**dē System may not work for everyone. There are additional risks associated with the moving the system. If it is decided to remove the system, another surgery will be required. Be sure to understand all the risks and benefits associated with the implantation of the **reme**dē System. For further information please visit remede.zoll.com, call 952-540-4470 or email info@remede.zoll.com. **Contraindications**: The **reme**dē System is contraindicated for use in patients with an active infection. See the Instructions for Use for complete information regarding the procedure, indications for use, contraindications, warnings, precautions, and potential adverse events. **Rx Only.** The **reme**dē[®] System, **reme**dē[®] EL System, and **reme**dē[®] EL Syst

The **rem**edē[®] System model 1001 has received CE Mark approval.

ZOLL MEDICAL CORPORATION

12400 Whitewater Dr., Suite 150 | Minnetonka, MN 55343 | 952-540-4470 | info@remede.zoll.com | remede.zoll.com

For subsidiary addresses and fax numbers, as well as other global locations, please go to www.zoll.com/contacts.

Copyright © 2023 ZOLL Medical Corporation. All rights reserved. Respicardia and **rem**edē are registered trademarks of ZOLL Respicardia, Inc. in the United States and/or other countries. ZOLL is a registered trademark of ZOLL Medical Corporation in the United States and/or other countries.



Printed in the U.S.A. MKT2020, Rev C